Cargando…
Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers?
A biochemical response index comprising ESR, CEA and CA 15.3 was evaluated in 67 patients with systemic breast cancer treated by chemotherapy; 55 were assessable by UICC criteria and the response index (96% of all UICC assessable patients). Marker changes at 2 and 4 months showed a highly significan...
Autores principales: | Dixon, A. R., Jackson, L., Chan, S. Y., Badley, R. A., Blamey, R. W. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968296/ https://www.ncbi.nlm.nih.gov/pubmed/8318411 |
Ejemplares similares
-
A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer.
por: Dixon, A. R., et al.
Publicado: (1992) -
Objective measurement of therapeutic response in breast cancer using tumour markers.
por: Robertson, J. F., et al.
Publicado: (1991) -
Potential for cost economies in guiding therapy in patients with metastatic breast cancer.
por: Robertson, J. F., et al.
Publicado: (1995) -
A comparison of the clinical metastatic patterns of invasive lobular and ductal carcinomas of the breast.
por: Dixon, A. R., et al.
Publicado: (1991) -
P-glycoprotein expression in locally advanced breast cancer treated by neoadjuvant chemotherapy.
por: Dixon, A. R., et al.
Publicado: (1992)